Skip to main content
Clinical Trials/NCT04761692
NCT04761692WithdrawnNot Applicable

Improving Vaccine Acceptance and Uptake Among Underresourced African American and Latinx Older Adults: A Multidisciplinary and Culturally Based Training Program for Minority Churches

Charles Drew University of Medicine and Science2 sites in 1 countryStarted: October 1, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Locations
2
Primary Endpoint
Prevalence of vaccination uptake for COVID-19, influenza, and pneumonia using Vaccination History Self Report

Study Overview

Brief Summary

This proposed study seeks to community knowledge and understand the experience of underserved communities in the exploration of reducing health disparities and increasing vaccine uptake and acceptability COVID-19, influenza, and pneumonia for AA and Latinx populations. Unique in its design, it has the following characteristics: 1) multifaceted, 2) culturally tailored, 3) community-based, and 4) mixed methods in which the outcomes of interest will be measured before and after the intervention with 18-month interval. Furthermore, we seek to enhance our partnerships and collaborations with churches in South Los Angeles by supporting efforts to encourage COVID-19, influenza, and pneumonia vaccination uptake among underserved minorities in one of the most challenged and hard-to-reach population areas in the nation.

Detailed Description

This study seeks to augment community knowledge and increase vaccine uptake among under-resourced African American and Latinx communities in South LA via leveraging trusted church leaders, educators and influencers to delivering COVID-19, influenza, and pneumonia education on vaccination. Unique in its design, this study has the following characteristics, beneficial to the acceptability and success of the proposal, it is: 1) multifaceted, 2) culturally tailored, and 3) community-based, in which the outcomes of interest will be compared longitudinally between arms 1-3, including measurement before and after the intervention with 9- and 18-month interval.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Health Services Research
Masking
None

Eligibility Criteria

Ages
65 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Parishioner at a church receiving the VEPMP intervention
  • Identify as African American or Latinx,
  • at least 65 years and older
  • Have Not received a vaccine for COVID-19, influenza, or pneumonia within the previous 24 months
  • Agrees to study terms, which include follow-up interviews 9 and 18 months after study enrollment

Exclusion Criteria

  • Does not attend or identify as a Parishioner at a church receiving the VEPMP intervention
  • Does not identify as African American or Latinx
  • Under the age of 65 years
  • Received all vaccine doses for COVID-19, influenza, or pneumonia within the previous 24 months

Outcomes

Primary Outcomes

Prevalence of vaccination uptake for COVID-19, influenza, and pneumonia using Vaccination History Self Report

Time Frame: Intervention: 12 months; Follow-up Point: 9 & 18 months post-intervention

By comparison of pre-, post- intervention, and 9- and 18-months follow-up data, we anticipate the following compared to baseline: a 30% change in uptake for vaccination.

Secondary Outcomes

  • Percentage of Participants Achieving Decreased Vaccine Hesitancy Levels of COVID-19, influenza, and pneumonia Using the NIH Toolbox Surveys on COVID-19, influenza, and pneumonia(Intervention: 12 months; Follow-up Point: 9 & 18 months post-intervention)
  • Percentage of Participants Achieving Adherence to COVID-19, influenza, and pneumonia vaccination schedules Risk Using the NIH Toolbox Surveys on COVID-19(Intervention: 12 months; Follow-up Point: 9 & 18 months post-intervention)
  • Percentage of Participants Achieving Decreased Levels of COVID-19, influenza, and pneumonia Mistrust and Barriers Using the NIH Toolbox Surveys on COVID-19, influenza, and pneumonia(Intervention: 12 months; Follow-up Point: 9 & 18 months post-intervention)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials